Teva’s Copaxone headache gets two-year reprieve

Date June 25, 2012

Jeremy Levin, the recently appointed CEO of the world’s biggest generics firm, Teva Pharmaceutical Industries, can sleep soundly again – for a couple of years, anyway.

The US district court ruling upholding key patents relating to the multiple sclerosis blockbuster Copaxone, which accounts for almost 20% of Teva’s global sales, secures another pillar of the company’s bid to defend the franchise. Had the decision gone the other way a combined $5.2bn of US Copaxone revenue in 2013/14 would have been put at risk. Moreover, Mr Levin has bought precious time to implement a lifecycle management strategy.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd